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A R T I C L E   I N F O S U M M A R Y 
In 2012, the United Nations (UN), identified chlorhexidine as a Life-saving 
Commodity and called for the development of a chlorhexidine product suitable 
for the prevention of omphalitis (umbilical cord infection) in developing 
countries. In response, GlaxoSmithKline (GSK) set out to develop a chlorhexidine 
digluconate 7.1% w/w gel, in partnership with Save the Children. The vision was 
to develop a gel which could pass a stringent regulatory review thereby assuring 
a safe, effective, and quality product. Review under the European Medicines 
Agency’s (EMA) Article 58 pathway was pursued, with accelerated assessment 
granted. The regulatory dossier compiled literature-based evidence for clinical 
efficacy and safety, supplemented by GSK-generated in-vitro studies and a full 
CMC data package to support the quality. No new clinical trial data or in vivo 
non-clinical study data were submitted. A positive opinion from the EMA was 
received in 2016. The time from the initial UN call to EMA Positive Opinion was 
3 years and 7 months. 
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INTRODUCTION 
The United Nations Commission Report on Life- 
saving Commodities for Women and Children, 
identified chlorhexidine for newborn cord care as one 
of thirteen lifesaving commodities (United Nations, 
2012). The newly cut umbilical cord is a common entry 
point for bacteria that can cause infection of the 
umbilical cord stump leading to neonatal sepsis and 
death. Umbilical cord infection (omphalitis) is most 
likely to occur in low income settings, primarily in 
developing countries in Africa and South Asia. There 
are significant gaps in access to this medicine due to 
limited awareness and demand. 
In direct response to the UN call, GSK set out to rapidly 
develop a chlorhexidine digluconate 7.1% w/w gel, in 
partnership with Save the Children. Chlorhexidine is a 
key ingredient in Corsodyl™ a GSK oral healthcare 
product. The vision was to develop a chlorhexidine gel 
which could pass a stringent regulatory review 
thereby assuring a safe, 
effective and quality product to fill gaps where there 
is no local manufacturing supply or insufficient 
supply due to quality or volume. 
The formulation and manufacturing processes were 
to be designed to be as simple as possible with an 
open source approach to share formulation and 
manufacturing knowledge with local companies to 
enable them to make the gel. 
MATERIALS AND METHODS 
GSK Consumer Health and Pharma R&D divisions 
collaborated to utilise both the extensive product 
knowledge base already available, e.g. API 
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degradation pathways and also their different 
experiences of speed and routes to market for a 
pharmaceutical product. 
The antiseptic ingredient (chlorhexidine digluconate) 
was reformulated from a solution product into a gel in 
a 3g single-use laminate sachet. Pictorial instructions 
are used to help mothers  and carers  in low literacy 
settings to apply the gel correctly. A published 
chlorhexidine gel formulation was simplified and 
optimised to minimise formation of impurities, in 
particular 4-chloroaniline (4-CA) which has been 
shown to be genotoxic and carcinogenic in non-clinical 
studies. (CICAD 2003) 
Efficacy is supported by three published community- 
based randomized controlled trials of chlorhexidine 
digluconate 7.1% solution in South Asia and a further 
non-inferiority study of chlorhexidine gel versus 
solution for antimicrobial efficacy (El-Arifeen S et al. 
2012; Hodgins S, 2010; Mullany L et al. 2006; Soofi S et 
al. 2012). These data were supplemented by literature 
reviews of clinical and nonclinical safety information. 
Three in vitro tests were performed with the gel 
formulation: antibacterial equivalency (kill time and, 
substantivity) and a skin-irritancy study, to bridge 
efficacy and safety data from the published studies of 
chlorhexidine solution to the gel product. 
In July 2013, the EMA in collaboration with the World 
Health Organisation (WHO), granted eligibility for the 
gel product to obtain a CHMP (Committee for Human 
Medicinal Products) Scientific Opinion through the 
Article 58 process.  This allows the issuance of a 
Certificate of Pharmaceutical Product (CPP) by the 
EMA to support national Marketing Applications as 
required. 
GSK worked with the EMA through the Scientific 
Advice process to agree the Clinical, Non-clinical, 
Quality and Regulatory strategy, including control of 
4-CA and drug product stability data package. In 
September 2015, the EMA granted an accelerated 
assessment, reducing the review period to 150 days. 
Regulatory filing was submitted in October 2015. 
In February 2016, a Managed Access (Compassionate 
Use) Programme was established in Bungoma county 
Kenya, in partnership with Save the Children to 
provide early access at the request of the Kenya 
Ministry of Health. The user acceptability study results 
will be used to advocate for national scale up in Kenya 
and help inform on use of chlorhexidine digluconate 
7.1% products in other countries. 
RESULTS AND DISCUSSION 
GSK rapidly developed a high quality Chlorhexidine 
Digluconate 7.1% w/w gel with a 2 year shelf-life 
suitable for climatic regions where the product is 
intended (and according to WHO recommendations) 
and where the supply chain logistics can be 
challenging. The regulatory dossier compiled 
literature-based evidence for efficacy, clinical and 
nonclinical safety, supplemented by GSK-generated in 
vitro studies. No new clinical trial data or in vivo non-
clinical study data were submitted. A CHMP positive 
opinion was achieved in April 2016 following EMA’s 
Article 58 procedure with accelerated assessment. The 
time from the UN call to the EMA Positive Opinion was 
3 years, 7 months.  
 
CONCLUSIONS 
GSK has developed Chlorhexidine Digluconate 7.1% 
w/w gel in a single-use sachet for prophylaxis of 
omphalitis. The path to approval was accelerated by: 
1) availability of published and internal knowledge of 
chlorhexidine; 2) leverage of the expertise of different 
product development route  from Consumer and R&D 
divisions ; 3) Engaging with the EMA through the 
Scientific Advice procedures; 4) use of published 
clinical trial data ; 5) accelerated EMA review of the 
Article 58 submission. 
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